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Elevations in C-reactive protein (CRP) are associated with an
increased risk of insulin resistance. Whether CRP plays a causal
role is unknown. Here we show that CRP transgenic mice and
wild-type mice administered recombinant CRP are insulin
resistant. Mice lacking the inhibitory Fcg receptor IIB (FcgRIIB)
are protected from CRP-induced insulin resistance, and immuno-
histochemistry reveals that FcgRIIB is expressed in skeletal mus-
cle microvascular endothelium and is absent in skeletal muscle
myocytes, adipocytes, and hepatocytes. The primary mechanism
in glucose homeostasis disrupted by CRP is skeletal muscle glu-
cose delivery, and CRP attenuates insulin-induced skeletal mus-
cle blood ﬂow. CRP does not impair skeletal muscle glucose
delivery in FcgRIIB
2/2 mice or in endothelial nitric oxide syn-
thase knock-in mice with phosphomimetic modiﬁcation of
Ser1176, which is normally phosphorylated by insulin signaling
to stimulate nitric oxide–mediated skeletal muscle blood ﬂow
and glucose delivery and is dephosphorylated by CRP/FcgRIIB.
Thus, CRP causes insulin resistance in mice through FcgRIIB-
mediated inhibition of skeletal muscle glucose delivery.
Diabetes 62:721–731, 2013
N
umerous clinical studies indicate that chronic,
mild increases in circulating levels of the acute-
phase reactant C-reactive protein (CRP) are
associated with insulin resistance (1–5). For
example, in middle-aged men, independent of numerous
risk factors including baseline BMI, individuals in the top
quintile of CRP (.4.18 mg/mL) had a more than threefold
greater risk of developing diabetes than those in the lowest
quintile (,0.66 mg/mL) (6). However, the relationship be-
tween CRP and type 2 diabetes has been greatly debated
(7–10), and whether CRP plays a pathogenetic role is un-
known.
In the current study, we determined how CRP inﬂuences
glucose homeostasis in vivo, testing the hypothesis that
CRP induces insulin resistance in mice. Additional studies
were performed to address the following questions:
 Which regulatory processes in glucose homeostasis are
altered by CRP?
 Is the effect of CRP on glucose homeostasis mediated by
Fcg receptors (FcgR) for IgG, which bind CRP to invoke
its cellular actions in certain paradigms (11,12)?
 How does CRP action via FcgR cause insulin resistance?
RESEARCH DESIGN AND METHODS
Animal model. Experiments were performed in male wild-type and CRP-
transgenic mice (TG-CRP) on CF-1 or C57BL/6 background (13–16), in endo-
thelial nitric oxide synthase (eNOS)-S1176D knock-in mice (formerly referred
to as eNOS-S1179D mice) (17,18), and in FcgRIIB
+/+,F c gRIIB
+/+;TG-CRP,
FcgRIIB
2/2, and FcgRIIB
2/2;TG-CRP littermates (C57BL/6 background) (19).
The transgene in the TG-CRP mouse consists of the protein-coding region of
the CRP gene linked to the promoter/regulatory region of phosphoenolpyr-
uvate carboxykinase (PEPCK). Although CRP expression can be enhanced by
providing these mice a carbohydrate-free diet, such a diet is not necessary for
the transgene to be expressed, and the mice fed normal chow display elevated
CRP levels (13–16). After weaning, all mice were fed normal chow (Taklad
Global 18% Protein Rodent Diet 2018). In select studies, enzyme-linked im-
munosorbent assays (ELISAs) were used to measure plasma CRP levels
(13,14), and levels of tumor necrosis factor-a (TNF-a), adiponectin, and leptin
(R&D System or Millipore). The care and use of all study animals was ap-
proved by the University of Texas Southwestern Institutional Animal Care and
Use Committee and conducted in accordance with Public Health Service
Policy on the Humane Care and Use of Laboratory Animals.
Glucose (GTT) and insulin tolerance tests (ITT). Mice were fasted for 4–6
h and injected intraperitoneally with D-glucose (1 g/kg body weight) for GTT or
with insulin (1 units/kg body weight) for ITT. Tail vein blood samples were
obtained at the indicated times for plasma glucose measurement by gluc-
ometer (ONE TOUCH Ultra2, Johnson & Johnson). Plasma insulin concen-
trations were determined by ELISA (Crystal Chem Inc.).
Glucose infusion rate (GIR). After a 5-h fast, euglycemic-hyperinsulinemic
clamps were performed with an insulin infusion at 20 mU/kg/min for 180 min.
Euglycemia (1.20–1.40 g/L) was maintained by measuring blood glucose every
10 min and adjusting a variable infusion of glucose. GIR was calculated as the
mean of the values administered in 10-min intervals during the 180-min in-
fusion period (20,21).
Administration of CRP. Mice were intraperitoneally injected with human
recombinant CRP (200 mg, Calbiochem) or an equal volume of vehicle (140
mmol/L NaCl, 20 mmol/L Tris-HCl, 2 mmol/L CaCl2, 0.05% NaN3, pH 7.5) every
other day for 14 days. This dose was chosen based on initial pharmacokinetic
studies indicating a CRP serum half-life of 5.3 h and that an intraperitoneal
dose of 200 mg yielded an average serum CRP of 31 mg/mL over the ensuing
48 h.
In vivo and ex vivo glucose uptake. In vivo glucose uptake was measured as
previously reported (22). Brieﬂy, fasted mice were injected intraperitoneally
with 2-deoxy-[
3H]glucose ([
3H]-2-DOG, Amersham; 2 g/kg; 10 mCi/mouse)
mixed with dextrose (20%), and blood glucose was measured at 0–90 min. The
plasma was deproteinized with ice-cold perchloric acid (3.5%), the supernatant
was neutralized with 2.2 mol/L KHCO3, and radioactivity was determined in
a liquid scintillation counter. The glucose-speciﬁc activity (degenerations/min/
mmol) was calculated by dividing the radioactivity by the glucose concentra-
tion, and the area under the curve (AUC) was integrated for the duration of the
experiment (90 min). Skeletal muscle (soleus and gastrocnemius) and
From the
1Division of Pulmonary and Vascular Biology, Department of Pedi-
atrics, University of Texas Southwestern Medical Center, Dallas, Texas; the
2Hypertension Section, Cardiology Division, Department of Internal Medi-
cine, University of Texas Southwestern Medical Center, Dallas, Texas; the
3Cardiovascular Research Center and Cardiology Division, Department of
Medicine, Massachusetts General Hospital and Harvard Medical School,
Boston, Massachusetts; and
4MacroGenics, Inc., Rockville, Maryland.
Corresponding author: Chieko Mineo, chieko.mineo@utsouthwestern.edu.
Received 9 February 2012 and accepted 17 August 2012.
DOI: 10.2337/db12-0133
This article contains Supplementary Data online at http://diabetes
.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0133/-/DC1.
 2013 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
See accompanying commentary, p. 688.
diabetes.diabetesjournals.org DIABETES, VOL. 62, MARCH 2013 721
ORIGINAL ARTICLEperigonadal white adipose tissue were harvested at 90 min. Peak plasma in-
sulin concentrations during the in vivo glucose uptake experiments were
0.25 6 0.03 nmol/L and 0.35 6 0.04 nmol/L for wild-type and TG-CRP mice,
respectively (13-week-old males, n =6 ;P = NS).
To measure tissue accumulation of 2-deoxy-[
3H]2DOG-6-phosphate
([
3H]2-DOG-6-phosphate), the harvested tissues were homogenized, and the
homogenate was precipitated in ice-cold perchloric acid (7%). After the cen-
trifugation, the supernatant was neutralized for 30 min with 2.2 mol/L KHCO3,
and two aliquots were prepared. One aliquot was used to determine total
3H
radioactivity. The other aliquot was passed through an anion exchange column
(AG 1-X8 resin; Bio-Rad Laboratories) to remove unbound [
3H]2-DOG-6-
phosphate. The column was washed with distilled water, and the radioactivity
in the eluted volume was measured in a scintillation counter. The difference
between total and eluted
3H radioactivity represents accumulated [
3H]2-DOG-
6-phosphate. The protein pellet was digested with 1N KOH, and protein con-
centration was determined by Bradford assay (Bio-Rad Laboratories). To
calculate [
3H]2-DOG uptake, the radioactive counts (degenerations/min) were
divided by the integrated glucose-speciﬁc activity AUC and the sample protein
content.
In ex vivo studies, basal and insulin-stimulated glucose uptake in soleus and
extensor digitorum longus muscle was measured as previously described (23).
Brieﬂy, the muscles were excised and incubated at 30°C in the absence or
presence of 2 nmol/L insulin for 40 min in Krebs-Henseleit buffer supple-
mented with 5 mmol/L Hepes, 0.1% BSA, and 2 mmol/L pyruvate. Muscles were
further incubated for an additional 20 min in Krebs-Henseleit buffer containing
1 mmol/L [
3H]2-DOG (2.5 mCi/mL) and 19 mmol/L [
14C]mannitol (0.7 mCi/mL)
at 30°C. After incubation, muscles were digested in 0.5 mol/L NaOH, and ex-
tracellular space and intracellular 2-deoxyglucose concentrations were de-
termined. Glucose uptake experiments were also performed as previously
described using 3T3L1 cells that were differentiated into adipocytes (24).
Insulin-induced skeletal muscle blood ﬂow. After a 5-h fast, mice were
anesthetized with isoﬂurane, and the left carotid artery was cannulated for
measurement of blood pressure and the right jugular vein for infusion of
glucose and insulin. The right femoral artery was exposed via a 1.5-cm incision
and separated from the femoral vein and nerve. The epigastric branch, which
provides blood ﬂow to the skin and adipose tissue but not to skeletal muscle,
was ligated. A 0.3-mm ﬂow probe was positioned over the femoral artery to
measure blood ﬂow, blood pressure, and heart rate using a pulsed Doppler
ﬂow system (Crystal Biotech, Holliston, MA). After a 45–60-min equil-
ibration period, a 180-min euglycemic-hyperinsulinemic clamp (blood glu-
cose 1.20–1.40 g/L) was performed with an insulin infusion at 20 mU/kg/min,
and blood ﬂow data were recorded throughout using Powerlab data acquisi-
tion software (ADInstruments, Bella Vista, Australia).
Hepatic glucose production. Surgical and experimental procedures are
previously described (25). Mice were surgically implanted with an indwelling
jugular vein catheter externalized on the nape of the neck and then recovered
for 5 days. Mice that lost .10% of presurgical body weight were not studied.
On the day of study, mice were transferred to a sterile shoebox-sized cage
lined with bedding at 9:00 A.M. to begin a 5-h fast. At t = 2120 min, water was
removed and a primed, continuous infusion of [3-
3H]glucose (5-mCi bolus +
0.05 mCi/min) was initiated. At t = 215 and 25 min, blood samples from the
cut tail were taken to measure basal fasted blood glucose, plasma insulin, and
glucose turnover. At t = 0 min, a continuous infusion of insulin (Humulin;
4 mU/kg/min) was used to induce hyperinsulinemia. The infusion of [3-
3H]
glucose was increased to 0.1 mCi/min to account for changes in speciﬁc ac-
tivity. Blood samples were taken every 10 min thereafter to measure blood
glucose. A variable GIR (50% dextrose) was used to maintain blood glucose at
;1.50 g/L. Additional blood samples were taken every 10 min during the
steady-state period (t = 80–120 min) to determine plasma insulin, endogenous
rate of glucose appearance, and rate of glucose disappearance. Endogenous
rate of glucose appearance and rate of glucose disappearance were calculated
using Steele’s non-steady-state Eqs (26,27). Plasma insulin concentrations
during the clamp were 0.14 6 0.05 and 0.15 6 0.04 nmol/L for wild-type and
TG-CRP mice, respectively (n =4 –6; P = NS).
Metabolic and body composition measurements. Indirect calorimetry and
locomotion data were simultaneously measured using the Comprehensive
Laboratory Animal Monitoring System (Columbus Instruments). Fat mass and
lean body mass were determined by NMR (Minispec NMR Analyzer; Bruker).
Quantitative PCR analyses. To evaluate FcgRIIB expression in pancreatic
islets, islets were isolated from wild-type CF1 mice (28), and quantitative real-
time PCR was performed using an Applied Biosystems 7900HT sequence de-
tection system and SYBR-green chemistry (Applied Biosystems, Foster City,
CA) with gene-speciﬁc primers (forward 59-TCCTCCTGATCTGGAAGAAGCT-39
and reverse 59-CGGGATGCTTGAGAAGTGAGT-39).
To evaluate inﬂammation genes and macrophage markers in adipose tissue,
totalRNAwasextractedandpuriﬁedfromepididymalwhiteadiposetissue,and
reverse transcription was performed, followed by real-time quantitative PCR
using a Roche LightCycler 480 and iQ SYBR Green Supermix (Bio-Rad). Rel-
ative amounts of target products were quantiﬁed by comparative CT method
(ΔΔCT), normalized to b-actin. Primer sequences were TNF-a: forward
59-CATCTTCTCAAAATTCGAGTGACAA-39 and reverse 59-TGGGAGTAGA-
CAAGGTACAACCC-39; interleukin (IL)-6: forward 59-GAGGATACCACTC-
CCAACAGACC-39 and reverse 59-AAGTGCATCATCGTTGTTCATACA; F4/80:
forward CTTTGGCTATGGGCTTCCAGTC-39 and reverse 59-GCAAGGAGGA-
CAGAGTTTATCGTG-39; and Mac-2: forward 59-ATGAAGAACCTCCGGG-
AAAT-39 and reverse 59-GCTTAGATCATGGCGTGGTT-39.
Immunohistochemical analyses. Expression of FcgRIIB was evaluated by
immunohistochemistry in tissues from FcgRIII
2/2 mice with a chimeric anti-
body (ch2.4G N297Q) directed to mouse FcgRIIB and FcgRIII. This antibody is
a modiﬁed 2.4G antibody in which Asn297 in the Fc domain has been mutated
to Gln to prevent Fc-FcR binding, thereby minimizing nonspeciﬁc binding.
A standard indirect immunoperoxidase horseradish peroxidase method was
used to incubate tissue sections with ch2.4G N297Q or an isotype-matched
negative control antibody, followed by peroxidase-conjugated secondary goat
anti-human (H+L) IgG (Jackson Immunoresearch). Slides were further in-
cubated with 3-amino-9 ethylcarbazole (Vector) and counterstained with Gill’s
hematoxylin. For immunoﬂuorescence analysis of FcgRIIB in skeletal muscle
from FcgRIIB
+/+ and FcgRIIB
2/2 mice, tissue sections were incubated with rat
anti-mouse CD31 (BD Pharmingen), followed by ch2.4G N297Q Alexa488
conjugated (MacroGenics) or an isotype-matched negative control antibody
overnight at 4°C. Slides were incubated with Cy3-conjugated donkey anti-rat
IgG (Jackson ImmunoResearch) for 1 h, washed in PBS, and mounted.
Statistical analysis. Comparisons between two groups were performed by
Student t tests. Differences between multiple groups were evaluated by one-
way ANOVA and Student-Newman-Keuls post hoc testing. Values shown are
mean 6 SEM. Signiﬁcance was accepted at the 0.05 level of probability.
RESULTS
CRP causes insulin resistance in mice. We ﬁrst studied
glucose and insulin homeostasis in 14–16-week-old male
wild-type controls and TG-CRP mice. Compared with
controls, fasting glucose and insulin levels were elevated
in TG-CRP mice (Fig. 1A and B). TG-CRP mice also dis-
played abnormal GTT (Fig. 1C) and ITT (Fig. 1D). Plasma
CRP levels were undetectable (,1 mg/mL) in controls and
were 3–14 mg/mL in TG-CRP mice. Abnormal GTT and ITT
were observed across the range of CRP levels studied (data
not shown). The GIR was measured during a euglycemic-
hyperinsulinemic clamp and was decreased .50% in TG-
CRP versus control mice (Fig. 1E). Thus, TG-CRP mice
with modest increases in CRP at levels known to be as-
sociated with the development of type 2 diabetes in
humans (1–4,6) have insulin resistance.
We next investigated the age at which TG-CRP mice
display abnormal glucose and insulin homeostasis and
evaluated the effect of CRP on body weight and compo-
sition. Both 5- and 13-week-old male TG-CRP mice dis-
played fasting hyperglycemia and hyperinsulinemia (Fig.
2A and B). At 5 weeks, TG-CRP mice had body weights
below those of wild-type mice and had a lower percentage
of fat mass (Fig. 2C–E). At 13 weeks, TG-CRP and wild-
type mice had similar body weights, but TG-CRP mice had
a greater percentage of fat mass. Therefore, TG-CRP mice
develop abnormal glucose and insulin homeostasis before
an increase in fat mass. Studies in metabolic chambers
revealed that TG-CRP mice did not have alterations in
oxygen consumption, CO2 production, respiratory ex-
change rate, heat production, or food intake compared
with wild-type mice (Supplementary Fig. 1A–E).
Plasma adiponectin levels were 8.69 6 0.54 and 9.31 6
0.46 mg/mL (n = 8/group), and leptin levels were 11.35 6
1.20 and 14.43 6 2.86 ng/mL (n = 8/group) in wild-type and
TG-CRP mice, respectively, indicating that they are not
altered by CRP in vivo. Plasma levels of TNF-a were un-
detectable in controls and in TG-CRP mice. There were
also no differences in mRNA abundance for TNF-a or IL-6
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tissue isolated from wild-type versus TG-CRP mice (data
not shown). Thus, CRP alone does not cause systemic in-
ﬂammation or promote inﬂammation in adipose tissue.
We next determined if the administration of CRP alters
glucose and insulin homeostasis in wild-type male mice
given recombinant human CRP or vehicle by intraperitoneal
injection every other day for 14 days. Whereas vehicle-
treated mice showed no changes, CRP-treated mice dis-
played fasting hyperglycemia and hyperinsulinemia on day
15 of the study (Fig. 3A and B). Shorter duration of CRP
treatment (7 or 11 days) did not alter fasting glucose or
insulin (data not shown). Body weight and fat and lean body
mass were not affected by CRP treatment (Fig. 3C–E).
These results provide further evidence that CRP causes
insulin resistance in vivo and that it does so independently
of changes in body composition.
FcgRIIB mediates CRP-induced insulin resistance.
The FcgRs are IgG receptors that invoke the cellular
actions of CRP in certain paradigms (11,12). To begin to
determine how CRP causes insulin resistance, we tested the
potential role of the inhibitory FcgR isoform designated
FcgRIIB (29) in studies of FcgRIIB
+/+;TG-CRP, FcgRIIB
2/2;
TG-CRP, FcgRIIB
+/+,a n dF c gRIIB
2/2 littermates. Fasting
glucose and insulin levels were elevated in FcgRIIB
+/+;TG-
CRP versus controls (FcgRIIB
+/+) but were normal in
FcgRIIB
2/2;TG-CRP mice (Fig. 4A and B). Furthermore,
GTT and ITT revealed that whereas FcgRIIB
+/+;TG-CRP
FIG. 1. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. Fasting plasma levels of glucose (A) and insulin (B)
were measured in wild-type (WT) or TG-CRP mice (14–16 weeks old; n = 10). Glucose tolerance tests (C) and insulin tolerance tests (D) were
evaluated, as were GIRs during euglycemic-hyperinsulinemic clamps with 20 mU/min/kg insulin (E)( n =5 –10). Values are mean 6 SEM. *P < 0.05
vs. wild-type.
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FcgRIIB
2/2;TG-CRP have normal glucose tolerance and
normal insulin sensitivity (Fig. 4C and D). Thus, FcgRIIB is
required for CRP-induced insulin resistance.
We next evaluated FcgRIIB protein distribution in tis-
sues from FcgRIII
2/2 mice with a chimeric antibody that
recognizes both mouse FcgRIIB and FcgRIII. Microvas-
cular endothelium in heart, brain, liver, and kidney dis-
played signal for FcgRIIB (data not shown). Importantly,
positive microvascular endothelial cell staining was
abundant in skeletal muscle (gastrocnemius) (Fig. 4E).
Staining was negative with control unrelated IgG or with
ch2.4G N297Q antibody applied to tissues from FcgRIIB
2/2
mice (Supplementary Fig. 2). In skeletal muscle there was
colocalization of the receptor with the endothelial cell
marker platelet endothelial cell adhesion molecule-1(Fig.
4F), whereas it was not detected in myocytes (Fig. 4E and
F, Supplementary Fig. 2), adipocytes, or hepatocytes (data
not shown). Thus, the microvascular endothelium in the
skeletal muscle is the well-recognized insulin target cell in
which FcgRIIB is expressed.
CRP blunts skeletal muscle glucose delivery. To de-
lineate the basis for the adverse effects of CRP on glucose
and insulin homeostasis, we evaluated numerous pro-
cesses. Wild-type and TG-CRP mice both had elevations in
plasma insulin in response to glucose (Fig. 5A), indicating
comparable capacity for pancreatic insulin secretion. This
ﬁnding is consistent with a lack of FcgRIIB mRNA ex-
pression in pancreatic islets (data not shown). We also
measured hepatic glucose production and found that CRP
did not alter basal production or the fall in production in
response to insulin (Fig. 5B).
We next determined if CRP affects tissue glucose de-
livery in studies of [
3H]-2-DOG uptake in perigonadal
white adipose tissue and gastrocnemius and soleus in
male mice aged 10–13 weeks. Glucose uptake in white
adipose was comparable in control and TG-CRP mice
(Fig. 5C). Consistent with this ﬁnding, CRP did not alter
glucose uptake in differentiated adipocytes in culture
(Supplementary Fig. 3). In contrast, TG-CRP mice dis-
played 39% less skeletal muscle glucose uptake than wild-
type mice (Fig. 5D). The selective impact of CRP on
FIG. 2. TG-CRP mice develop insulin resistance at an early age. Fasting plasma levels of glucose (A) and insulin (B), body weight (C), fat mass (D),
and lean body mass (E) were measured in wild-type (WT) and TG-CRP mice at the age of 5 or 13 weeks. Values are mean 6 SEM, n =6 .* P < 0.05 vs.
wild-type.
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apparent at age 5–6w e e k s( F i g .5 E and F). Having dis-
covered an abundance of FcgRIIB in skeletal muscle
microvascular endothelium (Fig. 4E and F; Supplemen-
tary Fig. 2), in which insulin activates eNOS (30,31) to
increase blood ﬂow and microvascular recruitment and
thereby promote glucose disposal (32–35), we next
studied insulin-induced skeletal muscle blood ﬂow in the
hind limb. Basal blood ﬂow was similar in control and
TG-CRP mice (0.339 6 0.152 and 0.234 6 0.08 cm/s,
respectively, n =5 ;P = NS). However, whereas insulin
infusion increased muscle blood ﬂow by 60% in control
mice (Fig. 5G), there was a complete lack of response in
TG-CRP mice. To then conﬁrm these ﬁndings by another
means, we studied the effect of CRP treatment in wild-
type mice. Whereas CRP administration did not affect
glucose delivery to white adipose tissue (Fig. 5H), glu-
cose delivery to skeletal muscle was decreased (Fig. 5I).
Thus, the primary mechanism in glucose homeostasis
disrupted by CRP is skeletal muscle glucose delivery, and
this is associated with an impaired response of the skel-
etal muscle vasculature to insulin.
FcgRIIB and eNOS antagonism mediate CRP impairment
of muscle glucose delivery. Because FcgRIIB, which is
required for CRP-induced insulin resistance (Fig. 4A–D), is
not expressed in skeletal muscle myocytes (Fig. 4E and F),
the decrease in muscle glucose delivery caused by CRP is
unlikely to be due to direct actions on insulin signaling in
myocytes. This conclusion was strengthened in ex vivo
studies of insulin-induced glucose transport in soleus and
extensor digitorum longus muscles (Fig. 6A and B), which
revealed similar insulin responses in muscles from wild-
type and TG-CRP mice. To further determine whether the
primary impact of CRP on glucose homeostasis occurs
through actions on endothelium, changes in in vivo glu-
cose uptake in response to CRP treatment were compared
in wild-type versus eNOS-S1176D knock-in mice express-
ing a phosphomimetic form of eNOS (18). Insulin signaling
in endothelial cells normally stimulates the phosphoryla-
tion of eNOS-S1176 (murine isoform, S1177 in human,
FIG. 3. Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Wild-type mice were
intraperitoneally injected with vehicle or CRP every other day for 14 days. On days 0 and 15, fasting plasma levels of glucose (A) and insulin (B),
body weight (C), fat mass (D), and lean mass (E) were measured. Values are mean 6 SEM, n =7 –14. *P < 0.05 vs. vehicle.
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(A) and insulin (B) levels were measured in FcgRIIB
+/+,F c gRIIB
+/+;TG-CRP, FcgRIIB
2/2, and FcgRIIB
2/2;TG-CRP littermates. Values are mean 6
SEM, n =4 –8. *P < 0.05 vs. FcgRIIB
+/+, †P < 0.05 vs. FcgRIIB
+/+;TG-CRP. Glucose tolerance tests (C) and insulin tolerance tests (D) were
performed in the same groups. Values are mean 6 SEM, n =4 –8. *P < 0.05 vs. FcgRIIB
+/+ at the indicated times. E: Expression of FcgRIIB in
skeletal muscle. Immunostaining for FcgRIIB was performed on gastrocnemius from FcgRIII
2/2 mice with chimeric antibody to mouse FcgRIIB and
FcgRIII (ch2.4G2, N297Q). Positive signal for FcgRIIB was detected in the microvascular endothelium (arrows) and was absent in skeletal muscle
myocytes. Scale bars = 50 mm. F:F c gRIIB expression in skeletal muscle was assessed by immunoﬂuorescence in tissue from FcgRIIB
+/+ vs.
FcgRIIB
2/2 mice. The skeletal muscle sections were probed with anti-FcgRII (green) and anti-platelet endothelial cell adhesion molecule-1
(PECAM-1; red) antibodies. Merged images are also shown. Scale bars = 50 mm. (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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cretion or hepatic glucose production. A: Pancreatic insulin secretion was evaluated in 10–13-week-old wild-type (WT) and TG-CRP mice. After an
intraperitoneal injection of D-glucose, plasma insulin levels were measured at the indicated times. Values are mean 6 SEM, n =8 .* P < 0.05 vs. wild-
type at the indicated time, †P < 0.05 vs. time 0. B: Hepatic glucose production was measured at baseline and during a hyperinsulinemic-euglycemic
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crease muscle blood ﬂow and microvascular recruit-
ment and thereby promote glucose disposal (33–35). In
prior work we showed that the CRP/FcgRIIB tandem
inhibits eNOS activation by causing eNOS-S1176 de-
phosphorylation (36,37). Therefore, the phosphomimetic
eNOS in eNOS-S1176D mice is resistant to CRP antago-
nism (18,36,37). CRP did not alter glucose uptake in white
adipose tissue of wild-type or eNOS-S1176D mice (Fig.
6C). However, whereas CRP blunted glucose uptake in the
skeletal muscle of wild-type mice, as previously observed
(Fig. 5D), uptake was unaffected by CRP in eNOS-S1176D
mice (Fig. 6D).
Now knowing that eNOS antagonism by CRP underlies
the impairment in muscle glucose disposal, and knowing
that FcgRIIB mediates CRP inhibition of eNOS (36,37), it
would be predicted that FcgRIIB is required for CRP to
blunt muscle glucose delivery. Additional glucose uptake
experiments were therefore performed in FcgRIIB
+/+;TG-
CRP, FcgRIIB
2/2;TG-CRP, FcgRIIB
+/+,a n dF c gRIIB
2/2
littermates. Glucose uptake in white adipose tissue was
comparable in the four groups (Fig. 6E), and as expected,
muscle glucose uptake was impaired in FcgRIIB
+/+;TG-
CRP versus FcgRIIB
+/+ mice (Fig. 6F). In contrast,
muscle glucose uptake was not adversely affected by
CRP in FcgRIIB
2/2;TG-CRP mice. These cumulative
ﬁndings indicate that CRP impairs skeletal muscle glu-
cose delivery, that this is caused by CRP attenuation of
the endothelial actions of insulin in skeletal muscle, and
that FcgRIIB in the muscle microvasculature mediates
this process.
DISCUSSION
Numerous studies have indicated that chronic, modest
elevations in CRP are associated with the development of
insulin resistance in humans (1–6). However, there has
been debate whether these associations are independent
of the relative degree of adiposity of the individual or an
epiphenomenon of obesity (7–10). Furthermore, it has
been unknown whether CRP is a pathogenetic factor in
insulin resistance. We therefore investigated the direct
effects of CRP on insulin sensitivity in mice and discov-
ered, using multiple strategies, that modest elevations in
CRP cause insulin resistance. These ﬁndings reveal an
entirely new modiﬁer of glucose homeostasis. When
combined with our prior observations that CRP causes
hypertension and impairs endothelial repair (13,14), these
ﬁndings also indicate that CRP may be a common etiologic
factor in the cardiovascular and metabolic disorders that
often complicate chronic inﬂammatory conditions.
In the current study, CRP-induced insulin resistance was
related to impaired skeletal muscle glucose delivery. This
mechanism may also underlie the trend toward insulin
resistance observed in TG-CRP mice fed normal chow in
a recent report that did not interrogate how CRP affects
insulin action (38). We reveal a mechanistic link between
the attenuated skeletal muscle glucose delivery and the
systemic insulin resistance caused by CRP because both
were normalized in FcgRIIB
2/2 mice. Importantly, pan-
creatic insulin production, hepatic glucose production
and insulin sensitivity, and adipose glucose uptake were
unaffected by CRP. Consistent with these observations, we
found that FcgRIIB is expressed in the skeletal muscle
microvasculature but not in skeletal muscle myocytes,
pancreatic islets, hepatocytes, or adipocytes. Also consis-
tent with a key role for altered skeletal muscle vascular
function and not altered myocyte function in CRP-induced
insulin resistance, we found that CRP does not inhibit
insulin-induced glucose uptake in isolated skeletal muscles
studied ex vivo. Moreover, the primary defect of impaired
skeletal muscle glucose delivery was fully prevented in the
eNOS-S1176D mice expressing a phosphomimetic eNOS
protected from CRP antagonism. From these multiple
ﬁndings we conclude that CRP-induced insulin resistance
is primarily due to impaired glucose delivery to skeletal
muscle caused by FcgRIIB-mediated inhibition of endo-
thelial insulin action.
Our current ﬁndings are consistent with the recognized
interrelationship between NO, insulin action in endothe-
lium, and metabolic homeostasis. The major aspects of the
metabolic phenotype of the TG-CRP mice mirror obser-
vations in eNOS
2/2 mice. The latter have a decreased GIR
during euglycemic-hyperinsulinemic clamping, blunted
insulin-induced skeletal muscle blood ﬂow, and skeletal
muscle glucose delivery that is decreased by 40% com-
pared with wild-type mice, whereas the response to insulin
in ex vivo studies of skeletal muscle glucose uptake is
normal (39). Furthermore, the attenuated skeletal muscle
glucose uptake and consequences on global insulin sensi-
tivity that we observe with CRP elevation are in close
agreement with a recent report in which insulin receptor
substrate 1 and 2 were both deleted from endothelium in
a cell-speciﬁc manner (40). This phenocopying strengthens
the evidence that the insulin resistance caused by CRP is
most likely primarily due to adverse effects on insulin
action in endothelium.
In addition to displaying insulin resistance, we discov-
ered that older TG-CRP mice (13 weeks old) have in-
creased fat mass. An increase in fat mass can contribute to
the development of insulin resistance (41,42). However,
this is not a primary mechanism in the current study be-
cause TG-CRP mice develop hyperglycemia and hyper-
insulinemia as early as age 5 weeks, when fat mass is not
increased, and the exogenous administration of recombi-
nant CRP for 2 weeks causes hyperglycemia and hyper-
insulinemia without affecting body composition. Mice with
muscle-speciﬁc inactivation of the insulin receptor have
increased fat mass (43), and the authors have speculated
that this is due to the increase in glucose transport to
adipose tissue also found in these mice (43). In TG-CRP
mice, glucose uptake in adipose tissue is not altered. The
basis for the increased adiposity found in older TG-CRP
mice is yet to be elucidated.
clamp (insulin – or +) in 10–13-week-old WT or TG-CRP mice with insulin infusion at 4 mU/kg/min. Values are mean 6 SEM, n =1 4 –15. *P < 0.05 vs.
no insulin. In vivo glucose uptake was evaluated in WT or TG-CRP mice at age 10–13 weeks (C and D), or at age 5–6 weeks (E and F). Mice were
injected intraperitoneally with [
3H]-2-DOG, and the speciﬁc accumulation of [
3H]-2-DOG-6-phosphate in white adipose tissue (WAT) isolated from
the perigonadal fat pad (C and E) and soleus and gastrocnemius (Sol + Gas) skeletal muscle (D and F) was determined. Values are mean 6 SEM,
n =5 –6. *P < 0.05 vs. WT. G: Skeletal muscle blood ﬂow was measured in 10–14-week-old WT or TG-CRP mice during a hyperinsulinemic-euglycemic
clamp with insulin infusion at 20 mU/kg/min. Values are mean 6 SEM, n =6 .* P < 0.05 vs 0 h, †P < 0.05 vs. WT at the indicated times. H and I: Effect
of exogenous CRP on in vivo glucose uptake. WT mice were injected with vehicle or CRP 2 h before intraperitoneal injection of [
3H]-2-DOG, and the
speciﬁc accumulation of [
3H]-2-DOG-6-phosphate in white adipose tissue (WAT) isolated from perigonadal fat pad (H) and soleus and gastroc-
nemius (Sol + Gas) skeletal muscle (I) was determined. Values are mean 6 SEM, n =6 .* P < 0.05 vs. vehicle.
CRP INDUCES INSULIN RESISTANCE VIA FCgRIIB
728 DIABETES, VOL. 62, MARCH 2013 diabetes.diabetesjournals.orgNow knowing that CRP causes abnormal glucose ho-
meostasis in mice and that FcgRIIB is critically involved,
the role of CRP in insulin resistance in humans can be
more effectively interrogated. Studies in lupus patients
indicate that genetic variations in human FcgRIIB are
common and that they impact receptor function (44),
and there is also great variability in Fc receptor gene copy
number (45). As such, there may be genetic modiﬁers
of CRP action in humans, and previous studies that
attempted to link CRP levels directly to phenotypes such
as insulin resistance may have been oversimpliﬁed. Ge-
netic variations in FcgRIIB can now be investigated to
better understand how CRP contributes to the pathogen-
esis of insulin resistance in humans.
FIG. 6. FcgRIIB and eNOS antagonism mediate CRP impairment of skeletal muscle glucose delivery. A and B: Ex vivo glucose uptake was evaluated
in isolated skeletal muscle in 10–13-week-old wild-type (WT) or TG-CRP mice. After muscles were harvested, basal and insulin-stimulated [
3H]-2-
DOG uptake in soleus (Sol) (A) and extensor digitorum longus (EDL) (B) were measured ex vivo. Values are mean 6 SEM, n =3 –5, *P < 0.05 vs. no
insulin. C and D: Lack of CRP-induced inhibition of skeletal muscle glucose uptake in eNOS S1176D mice. Wild-type (WT) mice or eNOS-S1176D
knock-in mice (10–13 weeks old) were injected with vehicle or CRP 2 h before an intraperitoneal injection of [
3H]-2-DOG, and the speciﬁc ac-
cumulation of [
3H]-2-DOG-6-phosphate in white adipose tissue (WAT) isolated from perigonadal fat pad (C) and soleus and gastrocnemius (Sol +
Gas) skeletal muscle (D) was determined. Values are mean 6 SEM, n =9 –11. *P < 0.05 vs vehicle. E and F: CRP impairment of in vivo skeletal
muscle glucose uptake requires FcgRIIB. Male FcgRIIB
+/+,F c gRIIB
+/+;TG-CRP, FcgRIIB
2/2, and FcgRIIB
2/2;TG-CRP littermates (10–13 weeks
old) were injected intraperitoneally with [
3H]-2-DOG, and the accumulation of [
3H]-2-DOG-6-phosphate in white adipose tissue (WAT) isolated
from the perigonadal fat pad (E) and soleus and gastrocnemius (Sol + Gas) skeletal muscle (F) was determined. Values are mean 6 SEM, n =4 –6.
*P < 0.05 vs FcgRIIB
+/+.
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vations in CRP cause insulin resistance in mice by de-
creasing skeletal muscle glucose delivery and that the
process is due to attenuated endothelial insulin action
mediated by FcgRIIB, which is abundant in skeletal mus-
cle microvascular endothelium. By targeting the common
underlying mechanism, namely endothelial dysfunction
caused by the CRP-FcgRIIB tandem, future therapies
aimed at CRP or its receptor may normalize the hyper-
tension and insulin resistance that often accompany
chronic inﬂammatory conditions.
ACKNOWLEDGMENTS
This work was supported by the American Diabetes
Association Grant 1-10-BS-124 (C.M.), National Institutes
of Health Grants HL-75473 (P.W.S.) and NS-33335 (P.L.H.),
the Donald W. Reynolds Cardiovascular Clinical Research
Center (W.V.), the O’Brien Kidney Center (W.V.), the
American Heart Association Scientist Development Grant
0835344N (D.N.A.), and the Children’s Medical Center of
Dallas Research Foundation (P.W.S.).
P.W.S. reports having received honoraria for participa-
tion in scientiﬁc meetings at which data in this article were
discussed. E.B. is an employee of MacroGenics, Inc.,
a company involved in the development of therapeutics
antibodies and whose ch2.4G N297Q antibody was used
in this study. No other potential conﬂicts of interest rele-
vant to this article were reported.
K.T. and C.M. conceived the study, did experimental
work, and wrote the manuscript. W.V. performed exper-
imental work and assisted in data analysis and interpre-
tation. J.A.B. performed quantitative RT-PCR analyses.
D.N.A. and P.L.H. created the eNOS knock-in mice used in
the study and assisted in data interpretation. E.B. contrib-
uted the monoclonal FcgRIIB antibodies, aided in the de-
sign of studies using the antibodies, and was involved in
manuscript preparation. P.W.S. was involved in study con-
ception, project planning, ﬁnancing, supervision, data anal-
ysis, and manuscript preparation. C.M. and P.W.S. are the
guarantors of this work and, as such, had full access to all
the data in the study and take responsibility for the integrity
of the data and the accuracy of the data analysis.
Parts of this study were presented at the Annual
Scientiﬁc Sessions of the American Heart Association,
Orlando, Florida, 14–18 November 2009.
The authors thank Christopher Longoria (University of
Texas [UT] Southwestern Medical Center) and Mohamed
Ahmed (UT Southwestern Medical Center) for technical
assistance, Dr. Daniela Rogoff (UT Southwestern Medical
Center) for her help in glucose uptake experiments, Dr.
Jen-Chieh Chuang (UT Southwestern Medical Center)
for pancreatic islet experiments, Dr. David Inuenza (Mac-
roGenics, Inc) and Junko Umetani (UT Southwestern
Medical Center) for immunohistochemical analysis, and
Dr. Amira Klip (The Hospital for Sick Children, Toronto,
Ontario, Canada) for providing them with L6-GLUT4myc
cells. The authors also thank Drs. Philipp Scherer, Joyce
Repa, Deborah Clegg, and Eric Berglund (all at UT
Southwestern Medical Center) for their helpful discussion.
REFERENCES
1. Haffner SM. Insulin resistance, inﬂammation, and the prediabetic state. Am
J Cardiol 2003;92:18J–26J
2. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM.
Chronic subclinical inﬂammation as part of the insulin resistance
syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circula-
tion 2000;102:42–47
3. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in
healthy subjects: associations with obesity, insulin resistance, and endo-
thelial dysfunction: a potential role for cytokines originating from adipose
tissue? Arterioscler Thromb Vasc Biol 1999;19:972–978
4. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive
protein is independently associated with fasting insulin in nondiabetic
women. Arterioscler Thromb Vasc Biol 2003;23:650–655
5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein,
interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;
286:327–334
6. Freeman DJ, Norrie J, Caslake MJ, et al.; West of Scotland Coronary
Prevention Study. C-reactive protein is an independent predictor of risk for
the development of diabetes in the West of Scotland Coronary Prevention
Study. Diabetes 2002;51:1596–1600
7. Greenﬁeld JR, Campbell LV. Relationship between inﬂammation, insulin
resistance and type 2 diabetes: ‘cause or effect’? Curr Diabetes Rev 2006;2:
195–211
8. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all
the answers? Am J Med 2007;120(Suppl. 1):S10–S16; discussion S16–S17
9. Haffner SM. The metabolic syndrome: inﬂammation, diabetes mellitus, and
cardiovascular disease. Am J Cardiol 2006;97(2A):3A–11A
10. Kahn SE, Zinman B, Haffner SM, et al.; ADOPT Study Group. Obesity is
a major determinant of the association of C-reactive protein levels and the
metabolic syndrome in type 2 diabetes. Diabetes 2006;55:2357–2364
11. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural
recognition and functional activation of FcgammaR by innate pentraxins.
Nature 2008;456:989–992
12. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and
role in inﬂammation. Clin Immunol 2005;117:104–111
13. Schwartz R, Osborne-Lawrence S, Hahner L, et al. C-reactive protein
downregulates endothelial NO synthase and attenuates reendothelializa-
tion in vivo in mice. Circ Res 2007;100:1452–1459
14. Vongpatanasin W, Thomas GD, Schwartz R, et al. C-reactive protein causes
downregulation of vascular angiotensin subtype 2 receptors and systolic
hypertension in mice. Circulation 2007;115:1020–1028
15. Lin CS, Xia D, Yun JS, et al. Expression of rabbit C-reactive protein in
transgenic mice. Immunol Cell Biol 1995;73:521–531
16. Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are
resistant to endotoxemia. Proc Natl Acad Sci USA 1997;94:2575–2580
17. Schleicher M, Yu J, Murata T, et al. The Akt1-eNOS axis illustrates the
speciﬁcity of kinase-substrate relationships in vivo. Sci Signal 2009;2:ra41
18. Atochin DN, Wang A, Liu VW, et al. The phosphorylation state of eNOS
modulates vascular reactivity and outcome of cerebral ischemia in vivo.
J Clin Invest 2007;117:1961–1967
19. Sundgren NC, Zhu W, Yuhanna IS, et al. Coupling of Fcg receptor I to Fcg
receptor IIB by Src kinase mediates C-reactive protein impairment of en-
dothelial function. Circ Res 2011;109:1132–1140
20. Vicent D, Ilany J, Kondo T, et al. The role of endothelial insulin signaling in
the regulation of vascular tone and insulin resistance. J Clin Invest 2003;
111:1373–1380
21. Cook S, Hugli O, Egli M, et al. Partial gene deletion of endothelial nitric
oxide synthase predisposes to exaggerated high-fat diet-induced insulin
resistance and arterial hypertension. Diabetes 2004;53:2067–2072
22. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose
transporter 4 selectively in muscle causes insulin resistance and glucose
intolerance. Nat Med 2000;6:924–928
23. Rogoff D, Ryder JW, Black K, et al. Abnormalities of glucose homeostasis
and the hypothalamic-pituitary-adrenal axis in mice lacking hexose-6-
phosphate dehydrogenase. Endocrinology 2007;148:5072–5080
24. Somwar R, Koterski S, Sweeney G, et al. A dominant-negative p38 MAPK
mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated
glucose uptake in 3T3-L1 adipocytes without affecting GLUT4 translocation.
J Biol Chem 2002;277:50386–50395
25. Hill JW, Elias CF, Fukuda M, et al. Direct insulin and leptin action on pro-
opiomelanocortin neurons is required for normal glucose homeostasis and
fertility. Cell Metab 2010;11:286–297
26. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH.
Chronic treatment with sildenaﬁl improves energy balance and insulin
action in high fat-fed conscious mice. Diabetes 2007;56:1025–1033
27. Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and
turnover rate of body glucose pool by the isotope dilution method. Am J
Physiol 1956;187:15–24
28. Chuang JC, Cha JY, Garmey JC, Mirmira RG, Repa JJ. Research resource:
nuclear hormone receptor expression in the endocrine pancreas. Mol
Endocrinol 2008;22:2353–2363
CRP INDUCES INSULIN RESISTANCE VIA FCgRIIB
730 DIABETES, VOL. 62, MARCH 2013 diabetes.diabetesjournals.org29. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275–
290
30. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions
of insulin related to production of nitric oxide in vascular endothelium.
Curr Diab Rep 2003;3:279–288
31. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor,
PI3-kinase, and Akt in insulin-signaling pathways related to production of
nitric oxide in human vascular endothelial cells. Circulation 2000;101:
1539–1545
32. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-
mediated skeletal muscle vasodilation is nitric oxide dependent. A novel
action of insulin to increase nitric oxide release. J Clin Invest 1994;94:
1172–1179
33. Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin
control its delivery to muscle and regulate the rate-limiting step in skeletal
muscle insulin action. Diabetologia 2009;52:752–764
34. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of
insulin. Endocr Rev 2007;28:463–491
35. Richards OC, Raines SM, Attie AD. The role of blood vessels, endothelial
cells, and vascular pericytes in insulin secretion and peripheral insulin
action. Endocr Rev 2010;31:343–363
36. Mineo C, Gormley AK, Yuhanna IS, et al. FcgammaRIIB mediates
C-reactive protein inhibition of endothelial NO synthase. Circ Res 2005;
97:1124–1131
37. Tanigaki K, Mineo C, Yuhanna IS, et al. C-reactive protein inhibits insulin
activation of endothelial nitric oxide synthase via the immunoreceptor
tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res
2009;104:1275–1282
38. Kaneko H, Anzai T, Nagai T, et al. Human C-reactive protein exacerbates
metabolic disorders in association with adipose tissue remodelling. Car-
diovasc Res 2011;91:546–555
39. Duplain H, Burcelin R, Sartori C, et al. Insulin resistance, hyperlipidemia,
and hypertension in mice lacking endothelial nitric oxide synthase. Cir-
culation 2001;104:342–345
40. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in en-
dothelial cells reduces insulin-induced glucose uptake by skeletal muscle.
Cell Metab 2011;13:294–307
41. Rajala MW, Scherer PE. Minireview: the adipocyte—at the crossroads of
energy homeostasis, inﬂammation, and atherosclerosis. Endocrinology
2003;144:3765–3773
42. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related
pathologies: the macro- and microcirculation of adipose tissue. FEBS J
2009;276:5738–5746
43. Kim JK, Michael MD, Previs SF, et al. Redistribution of substrates to adi-
pose tissue promotes obesity in mice with selective insulin resistance in
muscle. J Clin Invest 2000;105:1791–1797
44. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection:
evolutionary and therapeutic implications. Nat Rev Immunol 2010;10:
328–343
45. Bournazos S, Woof JM, Hart SP, Dransﬁeld I. Functional and clinical
consequences of Fc receptor polymorphic and copy number variants. Clin
Exp Immunol 2009;157:244–254
K. TANIGAKI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 62, MARCH 2013 731